The Food and Drug Administration will make a decision on whether to fully approve Eisai and Biogen’s Alzheimer’s treatment Leqembi by July 6, the companies announced Monday.
In a social media landscape shaped by hashtags, algorithms, and viral posts, nurse leaders must decide: Will they let the narrative spiral, or can they adapt and join the conversation?
...
